T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic tumor resulting
from the malignant transformation of immature T-cell progenitors. Originally associated with
a dismal prognosis, the outcome of T-ALL patients has improved remarkably over the last
two decades as a result of the introduction of intensified chemotherapy protocols. However,
these treatments are associated with significant acute and long-term toxicities, and the
treatment of patients presenting with primary resistant disease or those relapsing after a …